Implementation of Psychological Treatment in Generalized Anxiety (IMPLEMENT2_0)

May 19, 2022 updated by: University of Zurich

Design Development in Randomized Clinical Trials - Psychological Treatment in Generalized Anxiety

Pragmatic randomized controlled trial (expected N = 80) of cognitive-behavioral therapy (CBT) to contrast two psychotherapeutic implementation strategies (State-of-the-Art welcome phase vs. prolonged focus on sudden changes). Blinded allocation of implementation strategy for patients; open label for therapists (no blinding possible), randomized allocation for patients, therapist allocation via ABAB-design (crossed-therapist design). Post treatment self-reported outcome will be measured based on a latent outcome factor (i. e. "outcome composite").

Study Overview

Detailed Description

State of research. The proposed trial has a common theme, i.e., the understanding of the enduring efficacy of psychological treatments in individuals who suffer from general anxiety disorder (GAD). There is meta-analytic evidence that bona fide psychotherapy is an effective treatment for GAD, but also for individuals that suffers from anxiety and depression. Nonetheless, in spite of the empirical evidence of the overall efficacy, there is a lack of randomized controlled studies that systematically investigate the therapists' variability (i. e. therapist effects) within the very same treatment protocol. The development of study designs to investigate potential health professional effects along treatment effects is a general claim for human interventions. This protocol includes one of the very first process-outcome trials in GAD that systematically examine theory-based patients' and therapists' characteristics simultaneously using longitudinal multilevel methodology.

Along with investigating therapist and patient characteristics, two methods for timing the check-in phase at the beginning of each session will be compared by keeping constant the standardized treatment manual for patients with GAD: (a) prolonged focus on subtle changes check-in condition lasting from 7 to 20 minutes and (b) a state of the art (SOA) check-in phase lasting from 5 to 10 minutes. To address the nested data structure, therapists will be allocated by a single-subject ABAB-design. A total of 80 patients (40 participants in each of the two conditions) with a primary GAD diagnosis will be treated by 20 advanced cognitive-behavioral therapy trainees at the psychotherapy outpatient clinic in the department of psychology at the university of Zürich.

Relevance. (a) Study population. GAD is a neglected disorder in the Swiss mental health system. GAD is associated with personal suffering, a reduced quality of life, and high economic costs. (b) Design development. Systematic integration of potential therapist effects is a neglected aspect in many areas of evidence-based human interventions (inside but also outside of psychological interventions). (c) Treatment development. Evidence-based treatments are usually far from being fully efficacious. There is a debate about innovative research agendas and how to foster the efficacy of such treatments. (d) Experimental process-outcome research. There is a need for future research to investigate theory-based therapist effects and in-session timing within rigorous experimental process-outcome research designs to better understand the factors involved in therapeutic change (e.g. http://www.nature.com/news/therapy-deficit-1.11477).

Study Type

Interventional

Enrollment (Actual)

80

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Zurich, Switzerland, 8050
        • Department of Psychology, University of Zürich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. fulfill the diagnostic criteria for GAD based on the structured interview for DSM,
  2. are 18 years of age or older,
  3. Mastery of German language
  4. are seeking out a cognitive-behavioral therapy (CBT) for GAD at the outpatient clinic (Attenhoferstrasse 9) of the Institute for Psychology of the University of Zürich
  5. Informed consent as documented by signature

Exclusion Criteria:

  1. Acute Suicidal Ideation (BDI Suicide item > 1 or suicidal ideation in the telephone interview)
  2. Currently taking a psychotic or bipolar disorder medication, or
  3. Currently receiving treatment from a professional psychotherapist/psychiatrist.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: State of the art (SOTA) check-in phase
The therapists will apply the usual SOTA check-in phase lasting between 5 and 10 minutes, as recommended in the preexisting guideline including reviewing progress in self-help and agenda setting (Zinbarg et al., 2006).
The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.

In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.

The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment.

Other Names:
  • Cognitive Behavioral Therapy
EXPERIMENTAL: Prolonged focus on subtle changes
Based on the robust findings that over 90% of the patients will experience subtle changes, the therapists will extend the above mentioned check-in phase by systematized focus for 7 to 20 minutes capitalizing on small and subtle changes and exceptions.

In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.

The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment.

Other Names:
  • Cognitive Behavioral Therapy
Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change from baseline to 6 months treatment completion of a latent 5-facet, self-report outcome-factor
Time Frame: Baseline, treatment completion after 6 months (16 sessions)
Latent factor of the below-mentioned 5 self-report questionnaires (outcome composite)
Baseline, treatment completion after 6 months (16 sessions)

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Penn State Worry Questionnaire [PSWQ]
Time Frame: Baseline, treatment completion after 6 months (16 sessions)
Self-report worry inventory (Meyer et al., 1990)
Baseline, treatment completion after 6 months (16 sessions)
Beck Anxiety Inventory [BAI]
Time Frame: Baseline, treatment completion after 6 months (16 sessions)
Self-report anxiety inventory (Beck et al., 1988)
Baseline, treatment completion after 6 months (16 sessions)
Beck Depression Inventory II [BDI-II]
Time Frame: Baseline, treatment completion after 6 months (16 sessions)
Self-report depression inventory (Beck et al., 1996)
Baseline, treatment completion after 6 months (16 sessions)
Short version of the Symptom Check List [SCL-9]
Time Frame: Baseline, treatment completion after 6 months (16 sessions)
Self-report symptom severity index (Klaghofer & Brähler, 2001)
Baseline, treatment completion after 6 months (16 sessions)
Short version of the Resource Self-Report Questionnaire [RES]
Time Frame: Baseline, treatment completion after 6 months (16 sessions)
Self-report resource inventory (Troesken & Grawe, 2004)
Baseline, treatment completion after 6 months (16 sessions)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Christoph Flueckiger, Prof Dr., Department of Psychology, University of Zürich

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

January 1, 2017

Primary Completion (ACTUAL)

May 1, 2022

Study Completion (ACTUAL)

May 1, 2022

Study Registration Dates

First Submitted

January 12, 2017

First Submitted That Met QC Criteria

March 8, 2017

First Posted (ACTUAL)

March 14, 2017

Study Record Updates

Last Update Posted (ACTUAL)

May 26, 2022

Last Update Submitted That Met QC Criteria

May 19, 2022

Last Verified

May 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Generalized Anxiety Disorder

Clinical Trials on Implementation - SOTA

Subscribe